CORT125236

CORT125236 is an orally administered small molecule drug developed by Corcept Therapeutics. It is currently in Phase 1 clinical development, with studies conducted in healthy volunteers to assess its pharmacokinetics, metabolism, and safety profile[1][3][4]. The drug is being investigated as a potential treatment for solid tumors (cancer), particularly in combination with chemotherapy or other cancer medicines[7]. While the precise mechanism of action has not been explicitly detailed in public sources for CORT125236 itself, it belongs to a class of drugs known as selective glucocorticoid receptor antagonists—similar to other compounds from Corcept Therapeutics—which are designed to modulate cortisol activity by blocking the glucocorticoid receptor. This mechanism may help counteract pathologies resulting from overactive glucocorticoid signaling.